Illumina, Inc. (ILMN)
Health Care · Life Sciences Tools & Services · US stock · S&P 500 component
$262.54
▼ -5.39 (2.01%)
Fair valueData under review
$127
$64fair band $76–$178$191
Day's range
$259.26 – $272.01
52-week range
$93.50 – $309.35
About Illumina, Inc.
Illumina makes instruments, chemicals and software used to read DNA at scale. Its sequencing systems and the single-use consumables that run on them are used in research, clinical testing, cancer and genetic disease diagnostics, and drug discovery. Customers are academic and government laboratories, pharmaceutical and biotechnology firms and clinical labs. The company is based in San Diego.
Illumina earns money from instrument placements and from ongoing consumables and services that run on its installed base. Revenue is $4.5 billion over the last twelve months, but revenue growth over three years is -1.8% a year. The operating margin is 19.6%, and the business earns a profit of 20% on the capital invested in it. The company carries net debt of 0.9 times EBITDA and pays no dividend. On the site's X-Ray Score it receives 39 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $93.50 – $309.35Volume 2,489,000Daily, split-adjusted
Vitals
Market cap$40.2B
52-week range$93.50 – $309.35
Volume (last day)2,489,000
P/E (TTM)49.1
EBIT / EV yield2.2%
Free-cash-flow yield2.3%
Dividend yieldNo dividend
Revenue (TTM)$4.5B
Net income (TTM)$825M
Operating margin19.6%
Return on capital19.6%
Debt incl. leases$2.0B
Cash & securities$1.2B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$127model spread $121 – $134
Data under review
+0.0% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Earnings are far above the company's own 3-year history, so models would extrapolate a possible peak
Price $263
Undervalued < $76Fair $76 – $178Overvalued > $178
10-year DCF (market-scaled)
$118
Peer multiples
$135
Earnings power floor (not blended)
$-71
Fundamentals-adjusted multiple
$128
Growth the price implies
28.6%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Read the lenses below
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
12/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield2.2%
Free-cash-flow yield2.3%
Fair value vs price0.5×
Growth
Weak
30/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)-1.8%
Growth consistency40%
Profitability
Fair
56/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital19.6%
Operating margin19.6%
Gross profitability44.9%
Financial health
Fair
63/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA0.9×
Interest cover8.9×
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
-3.3%
Mar '25
-4.8%
Jun '25
+0.4%
Sep '25
+5.0%
Dec '25
+4.8%
Mar '26
+9.4%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.2B, diluted EPS $1.35.
Compare with peers
MTD Mettler Toledo Interna...50 A Agilent Technologies,...42 IQV Iqvia Holdings Inc.42 TECH BIO-TECHNE Corp40Other Life Sciences Tools & Services companies by X-Ray Score.
Fundamentals checklist
● 5 Good · ● 5 Average · ● 5 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldBad
Risk models
Altman Z''Average
Piotroski F-ScoreGood
Growth
Free-cash-flow growth (3y)Good
Revenue growth (3y)Bad
Growth consistencyBad
Balance sheet
Current ratioAverage
Net debt / EBITDAGood
Interest coverAverage
Valuation
Fair value vs priceBad
EBIT / EV yieldBad
Profitability
Return on invested capitalGood
Operating marginAverage
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 45/100.
Financials
| FY22 | FY23 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $4.5B | $4.6B | $4.5B | $4.4B | $4.3B |
| Operating income | −$123M | −$4.2B | −$1.1B | −$833M | $807M |
| Net income | $762M | −$4.4B | −$1.2B | −$1.2B | $850M |
| Operating cash flow | $545M | $392M | $478M | $837M | $1.1B |
| Operating margin | -2.7% | -91.2% | -23.7% | -19.1% | 18.6% |
| Free cash flow | $337M | $106M | $283M | $709M | $931M |
| Diluted EPS | $5.04 | $-28.00 | $-7.34 | $-7.69 | $5.45 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
9 bullish · 2 neutral · 5 bearish
Weekly
Strongly bullish
11 bullish · 0 neutral · 1 bearish
Monthly
Strongly bullish
7 bullish · 0 neutral · 1 bearish
Moving averages (daily)
| SMA 10 | 272.8 | Bearish |
| EMA 10 | 269.2 | Bearish |
| SMA 20 | 268.5 | Bearish |
| EMA 20 | 263.0 | Bearish |
| SMA 50 | 233.9 | Bullish |
| EMA 50 | 240.0 | Bullish |
| SMA 100 | 206.9 | Bullish |
| EMA 100 | 213.4 | Bullish |
| SMA 200 | 169.7 | Bullish |
| EMA 200 | 182.7 | Bullish |
Oscillators (daily)
| RSI (14) | 53.12 | Neutral |
| MACD (12, 26) | 10.41 | Bullish |
| Momentum (12) | -4.07 | Bearish |
| Stochastic %K (14) | 15.43 | Bullish |
| Williams %R (14) | -84.57 | Bullish |
| CCI (20) | -29.04 | Neutral |
Pivot points (classic, last session)
S3 244.4 | S2 251.9 | S1 257.2 | Pivot 264.6 | R1 269.9 | R2 277.4 | R3 282.7 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
ILMN SEC filings
13 Oct 2026
8-KSEC EDGAR
Entered a material agreement
17 Aug 2026
8-KSEC EDGAR
Other events
13 Aug 2026
8-KSEC EDGAR
Entered a material agreement
12 Aug 2026
8-KSEC EDGAR
Other events
7 Aug 2026
8-KSEC EDGAR
Other events
31 Jul 2026
10-QSEC EDGAR
Quarterly report
30 Jul 2026
8-KSEC EDGAR
Results of operations
23 Jun 2026
8-KSEC EDGAR
Director or officer change
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.